Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IDXX
stocks logo

IDXX

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
1.06B
+5.73%
3.283
+8.7%
1.05B
+7.16%
3.082
+10.06%
1.03B
+8.2%
2.837
+8.29%
Estimates Revision
The market is revising Upward the revenue expectations for IDEXX Laboratories, Inc. (IDXX) for FY2025, with the revenue forecasts being adjusted by 0.31% over the past three months. During the same period, the stock price has changed by 23.68%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.31%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.62%
In Past 3 Month
Stock Price
Go Up
up Image
+23.68%
In Past 3 Month
7 Analyst Rating
up Image0
Wall Street analysts forecast IDXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is 528.00 USD with a low forecast of 475.00 USD and a high forecast of 580.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
3 Hold
0 Sell
Moderate Buy
up Image0
Current: 523.920
sliders
Low
475.00
Averages
528.00
High
580.00
up Image0
Current: 523.920
sliders
Low
475.00
Averages
528.00
High
580.00
Stifel
Jonathan Block
Hold
maintain
$460 -> $510
2025-05-19
Reason
Stifel
Jonathan Block
Price Target
$460 -> $510
2025-05-19
maintain
Hold
Reason
Stifel analyst Jonathan Block raised the firm's price target on Idexx Laboratories to $510 from $460 and keeps a Hold rating on the shares after revisiting Q1 earnings reports across the analyst's Animal Health, Dental and Sleep Apnea coverage.
Stifel
Jonathan Block
Hold
Maintains
$450 → $420
2025-04-14
Reason
Stifel
Jonathan Block
Price Target
$450 → $420
2025-04-14
Maintains
Hold
Reason
Piper Sandler
David Westenberg
Hold
Maintains
$435 → $510
2025-02-10
Reason
Piper Sandler
David Westenberg
Price Target
$435 → $510
2025-02-10
Maintains
Hold
Reason
Piper Sandler raised the firm's price target on Idexx Laboratories to $510 from $435 and keeps a Neutral rating on the shares. The firm cites updated estimates and moving forward of its estimate year to 2026 from 2025.
B of A Securities
Michael Ryskin
Hold
Maintains
$475 → $535
2025-02-04
Reason
B of A Securities
Michael Ryskin
Price Target
$475 → $535
2025-02-04
Maintains
Hold
Reason
Barclays
Balaji Prasad
Buy
Maintains
$481 → $520
2025-02-04
Reason
Barclays
Balaji Prasad
Price Target
$481 → $520
2025-02-04
Maintains
Buy
Reason
Morgan Stanley
Erin Wright
Buy
Maintains
$559 → $550
2025-01-29
Reason
Morgan Stanley
Erin Wright
Price Target
$559 → $550
2025-01-29
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for IDEXX Laboratories Inc (IDXX.O) is 42.08, compared to its 5-year average forward P/E of 52.05. For a more detailed relative valuation and DCF analysis to assess IDEXX Laboratories Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
52.05
Current PE
42.08
Overvalued PE
64.58
Undervalued PE
39.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
36.26
Current EV/EBITDA
29.33
Overvalued EV/EBITDA
44.81
Undervalued EV/EBITDA
27.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
11.36
Current PS
9.91
Overvalued PS
13.85
Undervalued PS
8.87

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 764.05% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

IDXX News & Events

Events Timeline

(ET)
2025-05-01
09:55:01
Early notable gainers among liquid option names on May 1st
select
2025-05-01
07:11:41
Idexx Laboratories raises 2025 EPS view 19c to $11.93-$12.43, consensus $11.99
select
2025-05-01
07:10:05
Idexx Laboratories reports Q1 EPS $2.96, consensus $2.84
select
Sign Up For More Events
Sign Up For More Events

News

Preview
3.0
06-21NASDAQ.COM
IDXX Quantitative Stock Analysis

  • IDEXX Laboratories Stock Analysis: IDEXX Laboratories Inc (IDXX) is rated highly at 77% using the P/B Growth Investor model by Partha Mohanram, indicating strong potential for future growth based on its fundamentals and valuation in the Fish/Livestock industry.

  • Partha Mohanram's Contribution: Partha Mohanram, a notable academic in value investing, developed a growth model that challenges traditional views, focusing on identifying sustainable growth stocks through financial statement analysis.

Preview
3.0
06-12NASDAQ.COM
Guru Fundamental Report for IDXX

  • IDEXX Laboratories Performance: IDEXX Laboratories Inc (IDXX) has received a high rating of 77% from Validea's P/B Growth Investor model, indicating strong potential for sustained future growth based on its fundamentals and valuation in the Fish/Livestock industry.

  • Partha Mohanram's Influence: The growth model developed by Partha Mohanram, which challenges traditional views on growth investing, focuses on identifying stocks with low book-to-market ratios that are likely to continue their upward trajectory.

Preview
6.5
06-12Benzinga
IDEXX Laboratories Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

  • Analyst Ratings Overview: IDEXX Laboratories has received mixed analyst ratings over the past three months, with a current average price target of $517.00, reflecting a slight increase from previous estimates. Analysts have raised their ratings for some while lowering others, indicating varied expectations for the company's performance.

  • Financial Performance Insights: IDEXX Laboratories demonstrates strong financial metrics, including a net margin of 24.31% and a return on equity of 15.95%, although its revenue growth rate of 3.56% lags behind industry averages. The company maintains a balanced debt profile with a debt-to-equity ratio of 0.73.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is IDEXX Laboratories Inc (IDXX) stock price today?

The current price of IDXX is 523.92 USD — it has increased 0.78 % in the last trading day.

arrow icon

What is IDEXX Laboratories Inc (IDXX)'s business?

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.

arrow icon

What is the price predicton of IDXX Stock?

Wall Street analysts forecast IDXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is 528.00 USD with a low forecast of 475.00 USD and a high forecast of 580.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is IDEXX Laboratories Inc (IDXX)'s revenue for the last quarter?

IDEXX Laboratories Inc revenue for the last quarter amounts to 998.43M USD, increased 3.56 % YoY.

arrow icon

What is IDEXX Laboratories Inc (IDXX)'s earnings per share (EPS) for the last quarter?

IDEXX Laboratories Inc. EPS for the last quarter amounts to 2.96 USD, increased 5.34 % YoY.

arrow icon

What changes have occurred in the market's expectations for IDEXX Laboratories Inc (IDXX)'s fundamentals?

The market is revising Upward the revenue expectations for IDEXX Laboratories, Inc. (IDXX) for FY2025, with the revenue forecasts being adjusted by 0.31% over the past three months. During the same period, the stock price has changed by 23.68%.
arrow icon

How many employees does IDEXX Laboratories Inc (IDXX). have?

IDEXX Laboratories Inc (IDXX) has 11000 emplpoyees as of June 23 2025.

arrow icon

What is IDEXX Laboratories Inc (IDXX) market cap?

Today IDXX has the market capitalization of 42.46B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free